First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L42: Entry 114 of 127 File: JPAB Jan 9, 1992

PUB-NO: JP404005231A
DOCUMENT-IDENTIFIER: JP 04005231 A
TITLE: ANALGESIC FOR CHRONIC PAIN

PUBN-DATE: January 9, 1992

INVENTOR-INFORMATION:
NAME COUNTRY
TAKAGI, HIROSHI

ASSIGNEE-INFORMATION:
NAME COUNTRY
MORISHITA PHARMACEUT CO LTD
TAKAGI HIROSHI

APPL-NO: JP02106138
APPL-DATE: April 20, 1990

INT-CL (IPC): A61K 31/195

ABSTRACT:

PURPOSE: To provide the title analgesic usable effectively and safely for a long period of time, containing, as active ingredient, L-arginine.

CONSTITUTION: The objective analgesic containing, as active ingredient, L- arginine or its pharmaceutically acceptable salt. The dosage of the L-arginine is 50 - 700 (pref. 100 - 600) mg/kg/day for adult. The present analgesic is effective for herpes occipital pain, various central nervous pains, carcinomatous headache, cluster headache, cervico-brachial syndrome, humeral periarthritis, spondylosprain, spondylopathy deformans, rheumatic arthritis, etc.

Previous Doc Next Doc Go to Doc#

☐ **1:** Arthritis Rheum. 1994 Jul;37(7):1062-9.

N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats.

Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH.

University of Pittsburgh School of Medicine, PA 15261.

OBJECTIVE. To test the hypothesis that nitric oxide (NO) is involved in the pathophysiology of arthritis. METHODS. Arthritis was induced in male Lewis rats by the injection of adjuvant into the base of the tail. The NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (L-NMA), was administered daily by the oral route for 19 days. Paw swelling, plasma fibrinogen levels, and urinary NO2/NO3 levels were measured to assess the effect of L-NMA on the arthritic response and whole-body NO production, respectively. On day 20, the ankle joints were processed for histopathologic evaluation. RESULTS. The onset of clinical symptoms was preceded by elevated biosynthesis of NO. In a dose-dependent manner, L-NMA inhibited both NO biosynthesis and paw swelling; histopathologic changes in the ankle joints were also prevented. D-NMA had no effect on the development of arthritis, while L-arginine reversed the effects of L-NMA. Fibrinogen levels in rats with arthritis were unaffected by L-NMA. CONCLUSION. NO is critical to the development of both the inflammatory and erosive components of adjuvant arthritis in rats. There may be a future clinical role for suitable inhibitors of NO production or activity.

PMID: 7517676 [PubMed - indexed for MEDLINE]

First Hit Previous Doc Next Doc Go to Doc#

End of Result Set.

Generate Collection Print

L96: Entry 131 of 131 File: DWPI Feb 21, 1974

DERWENT-ACC-NO: 1974-15766V
DERWENT-WEEK: 200402

TITLE: Vitamin/hormone ointment - esp for skin disorders

PATENT-ASSIGNEE:

ASSIGNEE	CODE
ALBIN J F	ALBI

PRIORITY-DATA: 1972DE-2240187 (August 16, 1972)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 2240187 A	February 21, 1974		000	

INT-CL (IPC): A61K 9/06

ABSTRACTED-PUB-NO: DE 2240187A
BASIC-ABSTRACT:

Ointment contains vitamin A (axerophthol)(pref. 0.45 parts), vitamin B6 (pyridoxine hydrochloride) (pref. 0.25 parts), vitamin C (ascorbic acid) (pref. 1.00 part), vitamin D2 (calciferol) (pref. 0.15 parts), vitamin E (tocopheryl acetate) (pref. 0.30 parts), vitamin K 3 (sodium menadione bisulphite) (pref. 0.05 parts), progesterone (pref. 0.05 parts) and testosterone propionate (pref. 0.025 parts per thousand). It is suitable for the treatment of a variety of eye and skin disorders, including conjuctivitus, belpharitis, acne, psoriasis, seborrhoea, ulcus cruris etc., as well as haemorrhoids, fistulae, pruritis ani, anal fissures, phlegmones, gangrene, bruises, myalgias and muscular rheumatism.

TITLE-TERMS: VITAMIN HORMONE OINTMENT SKIN DISORDER

DERWENT-CLASS: B05

CPI-CODES: B01-C04; B01-C05; B03-L; B12-A07; B12-D09; B12-J04; B12-L04; B12-L05;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040223984 A1

Using default format because multiple data bases are involved.

L107: Entry 1 of 6 File: PGPB Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040223984
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040223984 A1

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 424/400; 514/177

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20040220160 A1

L107: Entry 2 of 6 File: PGPB Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040220160
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040220160 A1

10/765004
Yes

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 514/177; 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20040220154 A1

L107: Entry 3 of 6 File: PGPB Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040220154
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040220154 A1

TITLE: Topical testosterone formulations and associated methods 10/765003

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 514/171; 514/458

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20020150625 A1

L107: Entry 4 of 6 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150625
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150625 A1

10/021564 ↓ 6743448 NO.

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 424/489; 514/171, 514/458, 514/565

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 6743448 B2

L107: Entry 5 of 6 File: USPT NO. Jun 1, 2004

US-PAT-NO: 6743448
DOCUMENT-IDENTIFIER: US 6743448 B2

TITLE: Topical testosterone formulations and associated methods

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kryger; Abraham H.	Monterey	CA	93940	

US-CL-CURRENT: 424/489; 424/484, 424/486, 424/501

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

☐ 6. Document ID: WO 2055020 A2

L107: Entry 6 of 6 File: EPAB Jul 18, 2002

PUB-NO: WO002055020A2
DOCUMENT-IDENTIFIER: WO 2055020 A2
TITLE: TOPICAL TESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS

PUBN-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
KRYGER, ABRAHAM	

INT-CL (IPC): A61 K 0/
EUR-CL (EPC): A61K009/06; A61K031/195, A61K031/198 , A61K031/355 , A61K031/56 , A61K031/568 , A61K047/10 , A61K047/14 , A61K047/18 , A61K047/34

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L106 near2 abraham	6

Display Format: - Change Format

Previous Page Next Page Go to Doc#

1: Ann Rheum Dis. 1996 Nov;55(11):811-5. Related Articles, Links

Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis.

Booji A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW.

Department of Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands.

OBJECTIVE: To examine the possible beneficial effect of androgens in postmenopausal women with active rheumatoid arthritis. METHODS: 107 women participated in a double blind placebo controlled trial to evaluate the effect of 50 mg testosterone propionate intramuscularly every two weeks for one year. RESULTS: An improvement in ESR, Dutch health assessment questionnaire, and pain was noted. In addition, 21% of patients treated with testosterone fulfilled the ACR improvement criteria after one year, versus only 4% of the placebo group. The treatment was well tolerated. CONCLUSIONS: Testosterone may improve the general wellbeing of postmenopausal women with active rheumatoid arthritis.

Publication Types:
- Clinical Trial
- Randomized Controlled Trial